CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 47 enrolled
Drug / intervention
rituximabdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01153971
NCT01153971Phase 2Completed
CompareCT.gov

An Open-label Study of Fludarabine and Cyclophosphamide Plus MabThera Followed by Maintenance With MabThera on Failure-free Survival in Treatment-naïve Patients With Advanced Indolent B-cell Nonfollicular Lymphoma

Hoffmann-La Roche·interventional·Posted Jun 30, 2010·Updated Aug 1, 2017

In Brief

A Phase 2 clinical trial evaluating rituximab for Non-Hodgkin's Lymphoma. Completed, enrolled 47 participants across 15 sites.

Detailed Summary

This study will evaluate the efficacy and safety of MabThera in combination chemotherapy, followed by maintenance treatment with MabThera. The anticipated time on study treatment is 1-2 years, and the target sample size is \<100 individuals.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-Hodgkin's Lymphoma
CountriesItaly
Collaborators--

Timeline

Phase 2CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJun 30, 2010
Enrollment StartJul 20, 2005
Primary CompletionSep 24, 2010
TodayJul 2, 2026
Enrollment to primary: 5.2 yearsPosted 16.0 years ago

Interventions

rituximabdrug

1